Payment overview · 2025
General Payments
$936.28
46 reported records · 17 companies
Healthcare provider profile · identity verified
Paula Denise Stanley
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BONIFAY, FL · NPI 1669984654
Verified facts
What the public records show
CMS Open Payments records show Paula Denise Stanley received $936.28 in general payments during 2025 across 46 reported records.
PFIZER INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Nurtec Odt, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $160.16 | 17.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.63 | 16.2% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $118.90 | 12.7% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $87.02 | 9.3% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.32 | 8.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.09 | 5.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.65 | 4.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.10 | 4.2% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $33.83 | 3.6% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $32.23 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.46 | 3.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.75 | 2.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.64 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.20 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.34 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.52 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.44 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $936.28 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.01 | 8 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $93.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.25 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $87.02 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $76.81 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $76.32 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.38 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.20 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $33.83 | 1 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $32.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 177 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 607 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 87 |
| Lisinopril | Lisinopril | 501 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 117 |
| Gabapentin | Gabapentin | 440 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 81 |
| Losartan Potassium | Losartan Potassium | 346 | 80 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 299 | 84 |
| Furosemide | Furosemide | 289 | 60 |
| Simvastatin | Simvastatin | 277 | 53 |
| Potassium Chloride | Potassium Chloride | 275 | 67 |
| Metformin Hcl | Metformin Hcl | 269 | 54 |
| Montelukast Sodium | Montelukast Sodium | 249 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 231 | 41 |
| Trazodone Hcl | Trazodone Hcl | 198 | 50 |
| Glipizide | Glipizide | 195 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 48 |
| Carvedilol | Carvedilol | 193 | 39 |
| Buspirone Hcl | Buspirone Hcl | 187 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 184 | 34 |
| Famotidine | Famotidine | 182 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 29 |
| Eliquis | Apixaban | 177 | 34 |
| Promethazine Hcl | Promethazine Hcl | 177 | 84 |
| Fluoxetine Hcl | Fluoxetine Hcl | 176 | 35 |
| Allopurinol | Allopurinol | 161 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 32 |
| Clonazepam | Clonazepam | 159 | 31 |
| Sertraline Hcl | Sertraline Hcl | 155 | 29 |
| Celecoxib | Celecoxib | 151 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 144 | 33 |
| Alprazolam | Alprazolam | 142 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 129 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 28 |
| Topiramate | Topiramate | 124 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 24 |
| Diazepam | Diazepam | 120 | 25 |
| Donepezil Hcl | Donepezil Hcl | 114 | 19 |
| Methocarbamol | Methocarbamol | 113 | 37 |
| Tramadol Hcl | Tramadol Hcl | 111 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 68 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 86 | 20 |
| Meloxicam | Meloxicam | 81 | 25 |
| Farxiga | Dapagliflozin Propanediol | 78 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 76 | 21 |
| Lactulose | Lactulose | 76 | 24 |
| Mirtazapine | Mirtazapine | 76 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 14 |
| Levetiracetam | Levetiracetam | 74 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 74 | 13 |
| Alendronate Sodium | Alendronate Sodium | 71 | 16 |
| Doxepin Hcl | Doxepin Hcl | 71 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 30 |
| Atenolol | Atenolol | 70 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 68 | 16 |
| Pregabalin | Pregabalin | 68 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 18 |
| Amoxicillin | Amoxicillin | 64 | 58 |
| Entresto | Sacubitril/Valsartan | 64 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 51 |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 12 |
| Cilostazol | Cilostazol | 61 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 14 |
| Risperidone | Risperidone | 60 | suppressed |
| Cephalexin | Cephalexin | 59 | 50 |
| Temazepam | Temazepam | 59 | suppressed |
| Finasteride | Finasteride | 58 | 11 |
| Levofloxacin | Levofloxacin | 58 | 44 |
| Lamotrigine | Lamotrigine | 57 | 11 |
| Fluconazole | Fluconazole | 56 | 33 |
| Spironolactone | Spironolactone | 56 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 55 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 17 |
| Propranolol Hcl | Propranolol Hcl | 55 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Nystatin | Nystatin | 51 | 26 |
| Ezetimibe | Ezetimibe | 50 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 50 | 30 |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | 11 |
| Glimepiride | Glimepiride | 49 | 11 |
| Nitroglycerin | Nitroglycerin | 49 | 27 |
| Lurasidone Hcl | Lurasidone Hcl | 46 | suppressed |
| Vraylar | Cariprazine Hcl | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 35 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 15 |
| Digoxin | Digoxin | 37 | suppressed |
| Phenobarbital | Phenobarbital | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Baclofen | Baclofen | 35 | 12 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Zonisamide | Zonisamide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Diclofenac Potassium | Diclofenac Potassium | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 14 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Prednisone | Prednisone | 30 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 23 |
| Nabumetone | Nabumetone | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 17 |
| Torsemide | Torsemide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | 13 |
| Moxifloxacin | Moxifloxacin Hcl | 14 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $936.28 · 46 records | PFIZER INC. | AIRSUPRA, CAPLYTA, COBENFY, Cologuard Collection Kit, ELIQUIS, ENTYVIO, EVENITY, FANAPT, FARXIGA, GLASSIA, HYMPAVZI, JARDIANCE, LEQVIO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, Prolastin-C Liquid, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET, ZEPBOUND, Zemaira | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error